VT-3989 is under clinical development by Vivace Therapeutics and currently in Phase II for Malignant Pleural Mesothelioma. According to GlobalData, Phase II drugs for Malignant Pleural Mesothelioma have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how VT-3989’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
VT-3989 overview
VT-3989 is under development for the treatment of relapsed and refractory NF2 mutated malignant pleural mesothelioma and solid tumors. It is administered through the oral route as a capsule. The drug candidate acts by targeting Hippo-Yap pathway and yes-associated protein (YAP) and transcriptional enhanced associate domain (TEAD).
Vivace Therapeutics overview
Vivace Therapeutics is an oncology-focused small molecule drug discovery and development company. The company develops multiple novel small-molecule medicines targeting the Hippo-YAP pathway, which is involved in the regulation of cell proliferation, programmed cell death and cell migration. Vivace Therapeutics is headquartered in San Mateo, California, the US.
For a complete picture of VT-3989’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
